Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) Non Operating Investment Income (2019 - 2023)

Bioadaptives' Non Operating Investment Income history spans 5 years, with the latest figure at -$11.0 for Q4 2023.

  • For Q4 2023, Non Operating Investment Income fell 210.0% year-over-year to -$11.0; the TTM value through Sep 2024 reached -$11.0, up 47.62%, while the annual FY2023 figure was -$42.0, 71.62% up from the prior year.
  • Non Operating Investment Income for Q4 2023 was -$11.0 at Bioadaptives, roughly flat from -$11.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $5901.0 in Q4 2019 and bottomed at -$2517.0 in Q2 2021.
  • The 5-year median for Non Operating Investment Income is -$16.0 (2022), against an average of $162.35.
  • The largest YoY upside for Non Operating Investment Income was 887.22% in 2021 against a maximum downside of 621.2% in 2021.
  • A 5-year view of Non Operating Investment Income shows it stood at $5901.0 in 2019, then tumbled by 99.1% to $53.0 in 2020, then crashed by 379.25% to -$148.0 in 2021, then skyrocketed by 106.76% to $10.0 in 2022, then crashed by 210.0% to -$11.0 in 2023.
  • Per Business Quant, the three most recent readings for BDPT's Non Operating Investment Income are -$11.0 (Q4 2023), -$11.0 (Q3 2023), and -$10.0 (Q2 2023).